The SDDS is composed of two components: 1) intravenous injection of tumor CD44-targeted thermosensitive liposomes (TSL) preloaded with BML and Ptx, and 2) MW-induced hyperthermia to simultaneously achieve drug release and tumor ablation. This evidence concerns the gene CD44 and neoplasm.